Capital Square LLC Buys 848 Shares of Johnson & Johnson (NYSE:JNJ)

Capital Square LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 16.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 5,868 shares of the company’s stock after buying an additional 848 shares during the period. Capital Square LLC’s holdings in Johnson & Johnson were worth $862,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. IFS Advisors LLC increased its position in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares in the last quarter. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $29,000. Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $32,000. Finally, Conquis Financial LLC bought a new position in Johnson & Johnson in the 4th quarter valued at $33,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $153.95 on Thursday. The firm’s 50 day moving average price is $159.40 and its two-hundred day moving average price is $155.10. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The firm has a market cap of $371.00 billion, a P/E ratio of 23.15, a PEG ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. On average, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.38%. Johnson & Johnson’s payout ratio is presently 74.59%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Raymond James lowered their target price on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research note on Monday. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday. Barclays upped their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. Stifel Nicolaus lowered their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Finally, Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Nine investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $171.78.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.